Table 1 Baseline clinical characteristics of patients

Age (years)

59 ± 10

63 ± 8

61 ± 7

63 ± 8

Male

27 (55.1%)

36 (72%)

32 (64%)

21 (55.3%)

Weight (kg)

76 ± 13

74 ± 9

73 ± 9

68 ± 11

Nonparoxysmal AF

21 (42.9%)

19 (38%)

14 (28%)

26 (68.4%)

Coronary artery disease

10 (20.4%)

7 (14%)

4 (8%)

8 (21.1%)

Hypertension

24 (49%)

23 (46%)

28 (56%)

18 (47.4%)

Diabetes mellitus

6 (12.2%)

8 (16%)

10 (20%)

7 (18.4)

Heart failure

5 (10.2%)

2 (4%)

2 (4%)

5 (13.2)

Stroke/TIAs

4 (8.2%)

3 (6%)

4 (8%)

4 (10.5%)

CHADS₂ score

0.9 ± 0.8

0.8 ± 0.8

0.9 ± 0.8

0.9 ± 0.9

0

19 (38.8%)

21 (42%)

19 (38%)

15 (39.5%)

1

18 (36.7%)

20 (40%)

18 (36%)

11 (28.9%)

≥ 2

12 (24.5%)

9 (18%)

13 (26%)

12 (31.6%)

CHA₂DS₂-VASc score

1.8 ± 1.2

1.7 ± 1.3

1.7 ± 1.2

2.1 ± 1.6

HAS-BLED score

0.9 ± 0.9

0.9 ± 0.8

0.9 ± 0.7

1.0 ± 0.9

LAD (mm)

40 ± 6

41 ± 5

41 ± 6

42 ± 6

LVD (mm)

40 ± 6

47 ± 4

47 ± 4

46 ± 6

LVEF (%)

55 ± 9

57 ± 5

56 ± 5

55 ± 8

BNP (pg/mL)

176.6 ± 220.2

316.7 ± 396.8

179.9 ± 166.8

597.6 ± 753.2

Ccr (mL/min)

99 ± 19

93 ± 18

90 ± 23

90 ± 19

INR

1.1 ± 0.2

1.0 ± 0.1

1.0 ± 0.1

2.2 ± 0.9

TTR (%)

0

0

0

63.16

Thrombocyte (10⁹/L)

187 ± 47

203 ± 45

205 ± 49

206 ± 64

Hemoglobin (g/L)

145 ± 18

148 ± 18

145 ± 18

140 ± 17

Leukocyte (10⁹/L)

6.2 ± 1.6

6.4 ± 1.7

6.1 ± 1.5

5.9 ± 1.8

TG (mmol/L)

1.3 ± 0.6

1.5 ± 0.7

1.8 ± 1.8

1.7 ± 1.7

HDL (mmol/L)

1.2 ± 0.3

1.1 ± 0.2

1.2 ± 0.3

1.1 ± 0.2

LDL (mmol/L)

2.5 ± 1.5

2.3 ± 0.7

2.5 ± 0.6

2.3 ± 0.7

TC (mmol/L)

4.4 ± 1.0

4.3 ± 0.9

4.7 ± 1.0

4.3 ± 0.9

Anticoagulants (n)

 Dabigatran

13 (26.5%)

18 (36%)

17 (34%)

0 (0)

 Rivaroxaban

36 (73.5%)

32 (64%)

33 (66%)

0 (0)

Procedure time (min)

140 ± 42

131 ± 39

132 ± 38

138 ± 34

 X-ray dose (msv)

9 ± 4

10 ± 3

11 ± 5

13 ± 11

Ablation time (min)

104 ± 37

99 ± 31

99 ± 34

104 ± 32